Dianthus Therapeutics Inc
NASDAQ:DNTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth $-60.08 (169% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -27.8 | $87.16 |
0%
|
| Industry Average | 19.1 | $-60.08 |
-169%
|
| Country Average | 22.9 | $-71.82 |
-182%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$4.4B
|
/ |
Jan 2026
$-162.3m
|
= |
|
|
$4.4B
|
/ |
Dec 2026
$-233.6m
|
= |
|
|
$4.4B
|
/ |
Dec 2027
$-262.2m
|
= |
|
|
$4.4B
|
/ |
Dec 2028
$-288.5m
|
= |
|
|
$4.4B
|
/ |
Dec 2029
$-257.6m
|
= |
|
|
$4.4B
|
/ |
Dec 2030
$3m
|
= |
|
|
$4.4B
|
/ |
Dec 2031
$319m
|
= |
|
|
$4.4B
|
/ |
Dec 2032
$583.7m
|
= |
|
|
$4.4B
|
/ |
Dec 2033
$811.8m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Dianthus Therapeutics Inc
NASDAQ:DNTH
|
4.5B USD | -27.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 83.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 23.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 17.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 30.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Dianthus Therapeutics Inc
Glance View
Dianthus Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. Dianthus Therapeutics, Inc., formerly Magenta Therapeutics, Inc., is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies. The Company’s lead antibody, DNTH103, is engineered with an extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology, enabling less frequent and more convenient self-administered subcutaneous injections. DNTH103 is an investigational, long-acting monoclonal antibody engineered to potently and selectively inhibit the active form of C1s, a clinically validated target in the classical complement pathway. As the classical pathway plays a significant role in disease pathology across a range of neuromuscular disorders, DNTH103 holds the potential to be a pipeline in a product beginning with generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.
